Form 4: Moderna's Chief Legal Officer Reports Stock Option and Restricted Stock Unit Grants
SEC Form 4
Moderna's Chief Legal Officer, Shannon Thyme Klinger, reports the acquisition of stock options and restricted stock units.
Summary
- On February 27, 2024, Shannon Thyme Klinger, Chief Legal Officer of Moderna, Inc., reported transactions involving Moderna's securities.
- Klinger acquired 23,635 stock options with an exercise price of $96.20, vesting in installments starting February 27, 2025, and expiring on February 27, 2034.
- She also acquired 12,377 restricted stock units, vesting in installments starting February 27, 2025.
- Additionally, Klinger acquired 60,216 stock options with an exercise price of $96.20, vesting in installments starting February 27, 2026, and expiring on February 27, 2034.
- She also acquired 10,609 restricted stock units, vesting in installments starting May 27, 2024.
- Following these transactions, Klinger directly owns 7,912 shares of Moderna common stock, 23,635 stock options, 12,377 restricted stock units, 60,216 stock options, and 10,609 restricted stock units.
Sentiment
Score: 6
Explanation: The document is a standard regulatory filing detailing stock option and RSU grants. It's neutral in tone and reflects typical executive compensation practices.
Positives
- The granting of stock options and restricted stock units to the Chief Legal Officer aligns her interests with those of the shareholders.
- The vesting schedules of the options and RSUs incentivize long-term commitment and performance.
Industry Context
This filing is a routine disclosure of insider transactions, common for publicly traded companies like Moderna. It provides transparency into the compensation structure and equity ownership of key executives.
Comparison to Industry Standards
- Stock option and RSU grants are a common form of executive compensation in the biotechnology industry, used to incentivize performance and align executive interests with shareholder value.
- Companies like Pfizer, BioNTech, and Johnson & Johnson also utilize similar equity-based compensation plans for their executives.
- The vesting schedules described are fairly standard, with quarterly or annual vesting over a period of several years.
Stakeholder Impact
- The granting of stock options and restricted stock units can positively impact shareholders by aligning executive interests with company performance.
- Employees may view this as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 02/27/2024 | Date of the reported transactions: acquisition of stock options and restricted stock units. |
| 02/27/2025 | First vesting date for 25% of the first tranche of stock options and restricted stock units. |
| 02/27/2026 | First vesting date for 50% of the second tranche of stock options. |
| 02/27/2027 | Second vesting date for the remaining 50% of the second tranche of stock options. |
| 02/27/2034 | Expiration date for the stock options. |
| 05/27/2024 | First vesting date for 25% of the second tranche of restricted stock units. |
| 02/29/2024 | Date of the form filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.